静脉铁剂和含铁的磷酸盐结合剂对血清全段成纤维细胞生长因子 23 水平的影响差异。
Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.
机构信息
Division of Nephrology, Department of Medicine, Showa University Koto Toyusu Hospital, Tokyo, Japan,
Division of Dialysis, Suiyukai Clinic, Nara, Japan.
出版信息
Blood Purif. 2019;47 Suppl 2:63-69. doi: 10.1159/000496640. Epub 2019 Apr 3.
AIMS
This study assessed the impact of iron administration on serum fibroblast growth factor 23 (FGF23) levels.
METHODS
Of 123 hemodialysis (HD) patients treated with erythropoiesis-stimulating agents, 22 received once-weekly intravenous iron and 17 received daily oral iron with iron-containing phosphate binders. Intact FGF23 and biomarkers of iron metabolism were measured from blood samples drawn before each HD session, at baseline and on days 3, 5, 7, and 14.
RESULTS
Phosphate levels did not differ among the 3 groups during the 14-day period. Ferritin levels were significantly increased in both iron treatment groups compared with the non-iron treatment group, but changes in transferrin saturation levels were similar in the intravenous iron and non-iron groups. However, intact FGF23 levels were continuously higher in the intravenous iron group than those in the other groups.
CONCLUSION
Intravenous iron administration may influence intact FGF23 levels in HD patients independently of phosphate and iron metabolism.
目的
本研究评估了补铁对血清成纤维细胞生长因子 23（FGF23）水平的影响。
方法
在接受促红细胞生成素治疗的 123 名血液透析（HD）患者中，22 名患者接受每周一次的静脉铁治疗，17 名患者接受含铁磷酸盐结合剂的每日口服铁治疗。在每次 HD 治疗前、基线时以及第 3、5、7 和 14 天，从血液样本中测量完整的 FGF23 和铁代谢生物标志物。
结果
在 14 天期间，3 组之间的磷酸盐水平没有差异。与非铁治疗组相比，铁治疗组的铁蛋白水平显著升高，但静脉铁组和非铁组的转铁蛋白饱和度水平变化相似。然而，完整的 FGF23 水平在静脉铁组中持续高于其他组。
结论
静脉铁给药可能会独立于磷酸盐和铁代谢影响 HD 患者的完整 FGF23 水平。
Zotero 插件